CLINUVEL - injectable peptide platform in preclinical study
Filed with ASX · · 2 pages · English
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallCLINUVEL PHARMACEUTICALS LTD today announced that it has commenced dosing in its latest preclinical study with its controlled-release liquid injectable peptide formulation platform, VLRX-L. The VLRX-L platform has been designed to control the release of peptides – including CLINUVEL’s melanocortin-based drugs – through a flexible liquid dose. The pre-clinical study, focused on safety and kinetics,
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL expands Singapore RD&I Centre
- CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
- CLINUVEL advances new formulations in preclinical program
- CLINUVEL to advance novel pharmaceutical formulations in preclinical program
- EMA approves year-round SCENESSE treatment
Later from Clinuvel Pharmaceuticals
- Appendix 4D and Half Year Report
- CLINUVEL Record Revenues, Advances Strategic Expansion
- Half Year Results Presentation
- Chair Letter to Shareholders
- CLINUVEL's global programs showcased at AAD
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals